enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Pembrolizumab - Wikipedia

    en.wikipedia.org/wiki/Pembrolizumab

    Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 Inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...

  3. Is Summit Therapeutics a Buy Now? - AOL

    www.aol.com/summit-therapeutics-buy-now...

    Keytruda also has a tendency to come from behind when it comes to overall survival, which is the gold standard when it comes to evaluating a cancer therapy's efficacy. In the Keynote-042 trial ...

  4. PD-1 and PD-L1 inhibitors - Wikipedia

    en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

    Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...

  5. Checkpoint inhibitor - Wikipedia

    en.wikipedia.org/wiki/Checkpoint_inhibitor

    Pembrolizumab (brand name Keytruda) is another PD-1 inhibitor that was approved by the FDA in 2014 and was the second checkpoint inhibitor approved in the United States. [17] Keytruda is approved to treat melanoma and lung cancer and is produced by Merck .

  6. Where Will Merck Stock Be in 5 Years? - AOL

    www.aol.com/where-merck-stock-5-years-111500757.html

    In the second quarter, Keytruda sales climbed 16% year over year to $7.3 billion, benefiting from accelerating uptake. The result helped Q2 revenue increase by 7% over the same period.

  7. ‘No one should have to be fighting cancer and insurance at ...

    www.aol.com/no-one-fighting-cancer-insurance...

    Instead of being able to calmly focus on her chemotherapy treatment, Arete Tsoukalas had to spend hours on the phone arguing with her insurer while receiving infusions in the hospital. Diagnosed ...

  8. Microsatellite instability - Wikipedia

    en.wikipedia.org/wiki/Microsatellite_instability

    In May 2017 the FDA approved an immunotherapeutic called Keytruda (pembrolizumab) (PD-1 inhibitor) for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment.

  9. Merck Banks on Keytruda, Pipeline & Deals Amid Generic Woes - AOL

    www.aol.com/news/merck-banks-keytruda-pipeline...

    Keytruda, approved for several types of cancer, alone accounts for more than 25% of Merck's (MRK) pharmaceutical sales Animal health and vaccine products remain core growth drivers.